AstraZeneca sells Atacand rights to Cheplapharm for $400m

AstraZeneca said it was selling the commercial rights to its heart failure and hypertension drug Atacand and Atacand Plus in around 70 countries globally to Cheplapharm Arzneimittel for $400m.

The deal is expected to complete in the final quarter of 2020, AstraZeneca said on Friday, adding that $250m of the purchase price would be payable on completion and the rest in the first half of 2021.

.